GlobeNewsWire
24 Jun 2026, 18:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a class action lawsuit alleging securities fraud, including the use of channel stuffing to inflate revenues and undisclosed related party transactions. — Allegations of financial manipulation and internal control failures are fundamental risks to a company's valuation and credibility.
-0.80Culper Research reported that ADMA's reported 20% growth in 2025 was actually a 3% decline when adjusting for payment terms and channel stuffing. — A direct contradiction of growth narratives usually leads to significant valuation write-downs and investor exodus.
-0.70Cantor Fitzgerald downgraded ADMA Biologics from Overweight to Neutral following concerns over the Culper Research short report. — Analyst downgrades signal a loss of institutional confidence and typically trigger further selling pressure.
-0.50Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a class action lawsuit alleging securities fraud, channel stuffing, and internal control failures.
Mentioned at the end of the article as being subject to a case alleging false or misleading statements to investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
51m ago
